<div id="readability-page-1">The PRV was awarded after the US Food and Drug Administration(FDA) granted accelerated approvalfor the Kresladi (marnetegragene autotemcel) gene therapy.Kresladi comprises the patient’s own haematopoietic stem cells that are genetically modified to introduce functional copies of the ITGB2 gene.Rocket Pharmaceuticals expects to use the proceeds to support its cardiovascular gene therapy projects.These include clinical-stage studies for Danon disease, PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM), and BAG3-associated dilated cardiomyopathy (BAG3-DCM).A PRV is issued by the FDA to sponsors whose products address certain rare paediatric diseases.PRV holders may use it to seek an accelerated review for another marketing application or sell the voucher to a different sponsor.In February 2026, the programme was reauthorised, extending the availability of PRVs for qualifying therapies and maintaining incentives for rare paediatric drug development.Rocket Pharmaceuticals CEO Gaurav Shah said: “The monetisation of our PRV, following the FDA approval of Kresladi, provides meaningful non-dilutive capital and extends our cash runway into the second quarter of 2028. This strengthens our ability to advance key clinical milestones across our cardiovascular gene therapy pipeline, with all programmes on track.“We are deeply appreciative of the US Government’s continued recognition of the importance of therapeutic development for rare and often devastating paediatric disorders, which comprises an essential part of Rocket’s mission.”The sale forms part of the company’s ongoing strategy to manage capital and prioritise investment in selected gene therapy initiatives.The post Rocket to sell PRV for $180m to advance gene therapy pipeline appeared first on Pharmaceutical Business review.</div>

RCKT

SBIO

LABU

IBBQ

Rocket Pharmaceuticals plans to sell its Priority Review Voucher (PRV) for $180 million to fund its cardiovascular gene therapy projects, including studies for Danon disease and other conditions. The PRV was awarded after the FDA granted accelerated approval for Kresladi, a gene therapy using modified stem cells. CEO Gaurav Shah stated that this sale will provide non-dilutive capital, extending their cash runway into Q2 2028 and supporting key clinical milestones in their gene therapy pipeline.

Pharmaceutical Business Review

Rocket Pharma

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

ROCKET PHARMACEUTICALS INC C/WTS 02/09/2026 (TO PUR COM)

Rocket to sell PRV for $180m to advance gene therapy pipeline